ライフサイエンスコーパス: neuropsychiatric symptom

1 nts and substantially improves cognitive and neuropsychiatric symptoms.

2 ia), lethargy, parkinsonism, dyskinesias and neuropsychiatric symptoms.

3 d with respect to behavioural, cognitive and neuropsychiatric symptoms.

4 ike symptoms, hematologic abnormalities, and neuropsychiatric symptoms.

5 nfirmation will facilitate correlations with neuropsychiatric symptoms.

6 placebo (sham IVIG) in reducing severity of neuropsychiatric symptoms.

7 s for gastrointestinal, musculoskeletal, and neuropsychiatric symptoms.

8 g NFL athletes are related to later onset of neuropsychiatric symptoms.

9 sk are unclear in people not ascertained for neuropsychiatric symptoms.

10 w to diagnose, monitor, and treat its varied neuropsychiatric symptoms.

11 with physical dependency and the presence of neuropsychiatric symptoms.

12 s consisted of 29 patients with mTBI without neuropsychiatric symptoms.

13 tterns were seen for two major posttraumatic neuropsychiatric symptoms.

14 logy of tinnitus and connect tinnitus to the neuropsychiatric symptoms.

15 may provide therapeutic targets for specific neuropsychiatric symptoms.

16 of neural network excitability and triggers neuropsychiatric symptoms.

17 e absence of any history of strokes or other neuropsychiatric symptoms.

18 ral circuitry contributes to these disparate neuropsychiatric symptoms.

19 3 may serve as a target for the treatment of neuropsychiatric symptoms.

20 l candidates in this group and memantine for neuropsychiatric symptoms.

21 autism, epilepsy, cognitive impairment, and neuropsychiatric symptoms.

22 es than were most other medications used for neuropsychiatric symptoms.

23 exercise intervention significantly improved neuropsychiatric symptoms (-3.59, 95% CI -7.08 to -0.09)

24 MS results in motor, cognitive, and neuropsychiatric symptoms, all of which can occur indepe

25 ence of preoperative nonspecific somatic and neuropsychiatric symptoms and associated conditions was

26 Monitoring for neuropsychiatric symptoms and avoiding rechallenge are r

27 s with mild Alzheimer's disease and specific neuropsychiatric symptoms and behaviours measured by the

28 o both the presence or absence of individual neuropsychiatric symptoms and individual domain scores (

29 used to investigate the associations between neuropsychiatric symptoms and mortality, controlling for

30 Secondary outcome measures were overall neuropsychiatric symptoms and mortality.

31 Nondepressed with other neuropsychiatric symptoms and NOSYMP groups exhibited no

32 nset of the early features, characterized by neuropsychiatric symptoms and seizures preceded by a med

33 ury, autoimmune disorders, and infections to neuropsychiatric symptoms and suicidality is only beginn

34 ses caused by trinucleotide repeat expansion-neuropsychiatric symptoms and the phenomenon of genetic

35 performed to rule out medical causes of the neuropsychiatric symptoms and to ascertain whether any c

36 provide insight into the pathophysiology of neuropsychiatric symptoms, and contribute to monitoring

37 are prediabetes and the metabolic syndrome, neuropsychiatric symptoms, and low dietary folate.

38 adults, their correlation with cognitive and neuropsychiatric symptoms, and the accuracy of dementia

39 The association between neuropsychiatric symptoms (anxiety, depression, and fati

40 Specific neuropsychiatric symptoms are associated with shorter su

41 Neuropsychiatric symptoms are commonly associated with c

42 Cognitive impairment and neuropsychiatric symptoms are frequent in Parkinson's di

43 A variety of neuropsychiatric symptoms are highly prevalent in differ

44 nguishable from classic FTD or ALS, although neuropsychiatric symptoms are more prevalent and, for AL

45 decline, but the associated behavioural and neuropsychiatric symptoms are of equal importance in the

46 Neuropsychiatric symptoms are recognized to occur in a s

47 udy suggested a transient, modest benefit on neuropsychiatric symptoms as measured by the neuropsychi

48 ges in the degree of physical dependency and neuropsychiatric symptoms associated with recent admissi

49 ed both cognitive (simple reaction time) and neuropsychiatric symptoms at 1 day postinjury that resol

50 ged >/=70 years) individuals with or without neuropsychiatric symptoms at baseline.

51 Prevalence of neuropsychiatric symptoms, based on ratings on the NPI i

52 be considered in aPL-positive patients with neuropsychiatric symptoms, because use of antiaggregants

53 There were no differences in prevalence of neuropsychiatric symptoms between participants with Alzh

54 terase inhibitor drugs improve cognition and neuropsychiatric symptoms but the clinical response is u

55 Memantine also holds promise to treat neuropsychiatric symptoms, but more prospective trials a

56 lse Control disorders And the association of neuRopsychiatric symptoms, cognition and qUality of life

57 withdrawal symptoms) and clinical outcomes (neuropsychiatric symptoms, cognitive function, and quali

58 ention showed significantly worse outcome in neuropsychiatric symptoms compared with the group receiv

59 A syndrome of motoric and neuropsychiatric symptoms comprising various elements, i

60 Neuropsychiatric symptoms, depressive symptoms in partic

61 o=2.946), and any one clinically significant neuropsychiatric symptom (domain score >/=4, hazard rati

62 ion (hazard ratio=1.942), mildly symptomatic neuropsychiatric symptoms (domain score of 1-3, hazard r

63 evaluated the effect of citalopram on the 12 neuropsychiatric symptom domains assessed by the Neurops

64 hy, particularly with regard to arrhythmias, neuropsychiatric symptoms, dosing of dobutamine, and int

65 Recurrence rates of neuropsychiatric symptoms during the 1-year period were

66 clinical manifestations are acute attacks of neuropsychiatric symptoms frequently precipitated by dru

67 For patients in whom neuropsychiatric symptoms have been much improved or hav

68 ard ratio=1.448), and clinically significant neuropsychiatric symptoms (hazard ratio=1.951) were asso

69 The authors evaluated whether other neuropsychiatric symptoms improve with citalopram treatm

70 er cent of the participants did not have any neuropsychiatric symptom in the last month.

71 participants, 75% (n = 270) had exhibited a neuropsychiatric symptom in the past month (62% were cli

72 he absence of anti-MAP-2 was associated with neuropsychiatric symptoms in 19.7% of patients (P = 0.00

73 ositivity in both assays was associated with neuropsychiatric symptoms in 76.5% of patients, whereas

74 Neuropsychiatric symptoms in addition to schizophrenia,

75 Dementia and MCI are associated with neuropsychiatric symptoms in clinical samples.

76 are the first population-based estimates for neuropsychiatric symptoms in MCI, indicating a high prev

77 ined the link between clinically significant neuropsychiatric symptoms in mild Alzheimer's dementia a

78 The treatment of specific neuropsychiatric symptoms in mild Alzheimer's dementia s

79 own about the population-based prevalence of neuropsychiatric symptoms in mild cognitive impairment (

80 onship between aggressive behavior and other neuropsychiatric symptoms in patients with Alzheimer's d

81 to define the recurrence or continuation of neuropsychiatric symptoms in patients with Alzheimer's d

82 increased prevalence and early emergence of neuropsychiatric symptoms in patients with dementia with

83 brain ALA may be involved in generating the neuropsychiatric symptoms in porphyrias and that systemi

84 Study of neuropsychiatric symptoms in the context of dementia may

85 The neuropsychiatric symptoms in the former group included p

86 43% of MCI participants (n = 138) exhibited neuropsychiatric symptoms in the previous month (29% rat

87 alternatives for the long-term treatment of neuropsychiatric symptoms in these patients.

88 o network malfunction leading to progressive neuropsychiatric symptoms in TSC.

89 ry interventions and interventions to reduce neuropsychiatric symptoms, including depression, that in

90 imer's disease (AD) is associated with other neuropsychiatric symptoms, including severe depression.

91 nts is associated with the severity of these neuropsychiatric symptoms is unknown.

92 e disorder (OCD) cases exhibiting additional neuropsychiatric symptoms, it was proposed that neuroinf

93 The detection of early neuropsychiatric symptoms might be a marker for dementia

94 depressed (n = 44), nondepressed with other neuropsychiatric symptoms (n = 93), and no-symptom (NOSY

95 ne patients with SLE with a history of overt neuropsychiatric symptoms (neuropsychiatric SLE [NPSLE])

96 NPSLE), 22 SLE patients without a history of neuropsychiatric symptoms (non-NPSLE), and 25 healthy co

97 [NPSLE]), 22 patients with SLE without overt neuropsychiatric symptoms (non-NPSLE), and 25 healthy co

98 outcomes were: 12 weeks CMAI; 6 and 12 weeks Neuropsychiatric symptoms (NPI), Clinical Global Impress

99 Thirty-one SLE patients with a history of neuropsychiatric symptoms (NPSLE), 22 SLE patients witho

100 x behaviours as a 'lesion-based' approach to neuropsychiatric symptoms observed across diagnostic cat

101 responsible for the transient and permanent neuropsychiatric symptoms observed in patients with SLE.

102 Neuropsychiatric symptoms occur in the majority of perso

103 Apathy was the key neuropsychiatric symptom occurring most often in advance

104 Neuropsychiatric symptoms of Alzheimer's disease seem to

105 The behavioral and neuropsychiatric symptoms of dementia and Alzheimer's di

106 Use of atypical antipsychotics for neuropsychiatric symptoms of dementia increased markedly

107 vatives as alternative agents to address the neuropsychiatric symptoms of dementia may carry associat

108 wing new antipsychotic medication starts for neuropsychiatric symptoms of dementia were compared with

109 Many neuropsychiatric symptoms of fragile X syndrome (FXS) ar

110 stimulation in psychiatric disorders and the neuropsychiatric symptoms of Parkinson's disease, these

111 macological intervention is unsuccessful and neuropsychiatric symptoms or associated behaviors cause

112 remains difficult to accurately elucidate if neuropsychiatric symptoms or conditions are indicators o

113 The presence of neuropsychiatric symptoms or lower serum folate levels p

114 The authors sought to determine which neuropsychiatric symptoms predict relapse.

115 h hepatitis C virus infection as well as the neuropsychiatric symptoms related to hepatitis C and IFN

116 lder adults, suggesting that loneliness is a neuropsychiatric symptom relevant to preclinical AD.

117 Increases in pain were associated with worse neuropsychiatric symptom scores within all groups.

118 otor and vocal tics and certain of the other neuropsychiatric symptoms seen in Tourette syndrome are

119 ents with encephalopathy plus one or more of neuropsychiatric symptoms, seizures, movement disorder o

120 Neuropsychiatric symptoms such as agitation and delusion

121 Post-Concussion Syndrome, a constellation of neuropsychiatric symptoms that includes depression, anxi

122 ion effect or the pathophysiology underlying neuropsychiatric symptoms that prompt antipsychotic use.

123 y, up to 75% of patients with SLE experience neuropsychiatric symptoms that range from anxiety, depre

124 Severity of delusions and other neuropsychiatric symptoms was assessed by using a semist

125 The course of neuropsychiatric symptoms was prolonged and often associ

126 Sixty individuals with SLE and no overt neuropsychiatric symptoms were administered ANAM to dete

127 the Katz Activity of Daily Living index, and neuropsychiatric symptoms were assessed through The Neur

128 n Cognitive Decline in the Elderly (IQCODE); neuropsychiatric symptoms were evaluated using the Neuro

129 Neuropsychiatric symptoms were rated using the Beck Depr

130 ients presenting with tinnitus commonly have neuropsychiatric symptoms with which physicians need to